Thread: Diagenic,Maybe one of the best Invest 2008

Diagenic will be one of the winner on the stock markets 2008!

DiaGenic ASA is in the process of commercialisation for their two first
diagnostic products; tests for breast cancer (BC) and Alzheimer’s
disease (AD). For BC the first revenues should be realised in second
half of 2008, following the commercial launch of the product in India.
Commercialisation of the AD test will continue in parallel, with first
revenues expected in 2009, after CE marking of the product.
EUROPEAN PATENT ALZHEIMER’S DISEASE
The patent when granted will be valid in 19 European countries and cover
the use of differentially expressed informative probes for diagnostic
purposes.

Diagenic will rise soon,My advice Invest you money
in next week ! Maybe one of the best Invest you can do for 2008.

oslo Stock Exchange
http://www.euroland.com
http://www.diagenic.com/


Hot Trigger:
EBCC-6 (European Breast Cancer Conference
Berlin, Germany - 15-19 April

Trigger:
1) 12-19/4: American Academy of Neurology, Chicago, IL, USA.
2) 15-19/4: EBCC-6, Berlin, Germany.
3) 19-21/5: Biomarker World congress, Philadelphia, PA, USA
4) 22-25/5: 18th Alzheimer Europe Conference, OSLO, NORWAY !
5) 30/5-3/6: American Society of Clinical Oncology, Chicago, IL, USA
6) 4-8/6: 5th World Conjference on Breast Cancer, Winnipeg, Canada.
7) 17-20/6: Bio 2008, San Diego, CA, USA.

Read this:
Oslo Stock Exchange
DiaGenic's shares are listed on the Oslo Stock Exchange under the ticker "DIAG
15.02.2008 Presentation of the fourth quarter 2007 report.
This stock will soon explode,you can buy it very cheap now in Oslo Stock Exchange!

A major breast cancer study in India that was set up by PAC Med Biotech on behalf of DiaGenic ASA is nearing completion on schedule. PAC Med Biotech is now coordinating the business entry of DiaGenic's blood-based breast cancer screening and diagnostic test through talks with major laboratory chains and pharmaceutical companies for a planned launch in mid 2008

The DiaGenic breast cancer blood test offers a unique range of advantages over existing methods. Firstly, the use of venous blood as the test-sample is patient friendly. The test also detects breast cancer in pre-menopausal women with good accuracy whereas mammography has major problems due to high breast density which obscures the mammographic image. This is especially important in India, where breast cancer is seen at a significantly lower age than in Western countries. Finally, the disease can be discovered at a very early stage, thus paving the way for effective intervention.

And this:
EUROPEAN PATENT ALZHEIMER’S DISEASE
Today DiaGenic received Notice of Allowance from European Patent Office
for its method of diagnosing Alzheimer’s disease using blood samples and
gene expression technology.
The patent when granted will be valid in 19 European countries and cover
the use of differentially expressed informative probes for diagnostic
purposes. The method of probe selection is general and not limited to
any one particular mode of selection. Earlier DiaGenic had received a
European patent, EP0979308, covering only the use of informative probes
isolated by non-sequence based methods for diagnostic purposes.
Also, DiaGenic has recently been notified by the Indian and Australian
Patent Authorities that they have accepted the claims comprising the use
of important gene sequences in the detection of, among others, breast
cancer and Alzheimer’s disease (parent application, PCT/GB03/005102).
MD PhD Erik Christensen, managing director of DiaGenic comments,“The
new European patent for diagnosis of Alzheimer’s disease is an important
milestone which strengthens our position in this region. The company
will now have similar patent protection in Europe and in the United
States. The growing patent portfolio reflects our active patent strategy
and confirms DiaGenic a leader in the field of molecular diagnostics
utilizing blood-based tests. The new patents also make DiaGenic an
attractive partner for a long period of time, since commercial
agreements are typically entered into for the lifetime of the patents”.


How to buy shares on the oslo stock exchange?

If your broker is any good this should be no problem. Just give him the full stock name and place the order. I believe there is very limited hours of trading, but again leave this to them. The usual problems are not in trading but in settlement, but again a good broker should have this covered.

The norwegian stock exchange is open to international investors, just go to any international bank and tell them which norwegian stocks you want to buy!

Diagenic stock price Today/DIAGENIC(Oslo: DIAG.OL

http://finance.yahoo.com/q?s=DIAG.OL

Diagenic in bioArray news!:

from BioArray News: Patent Allowances in EU, India, Australia Enable DiaGenic to Begin Selling Its Dx
Patent Allowances in EU, India, Australia
Enable DiaGenic to Begin Selling Its Dx
[April 15, 2008]
By Justin Petrone
DiaGenic this week said that it has received a notice of allowance from the European Patent Office for its gene expression-based Alzheimer’s disease diagnostic.
When granted, the patent will be valid in 19 European countries and cover the use of differentially expressed informative probes for diagnostic purposes, the Norwegian life-sciences company said.
DiaGenic previously received a European patent, EP0979308, covering only the use of informative probes isolated by non-sequence-based methods for diagnostic purposes.
“From our point of view it is a real milestone for several reasons,” CEO Erik Christensen said this week. He said that not only will the newly awarded IP protect the company from potential litigation, it will also make it a more attractive partner for future diagnostics collaborations.
The Europe allowance comes as the company seeks to protect its IP ********* as it transitions its focus from research and development to commercialization. For instance, DiaGenic has recently been notified that the Indian and Australian patent authorities have accepted the claims comprising the use of gene sequences in the detection of, among other indications, breast cancer and Alzheimer’s disease.
In 2004, the US Patent Office awarded DiaGenic a patent to use gene-expression signatures to diagnose Alzheimer’s disease, and the European patent similarly covers the use of expression signatures. However, Christensen said that the European patent includes the use of “more modern, non-sequencing base methods,” and said the allowance will be a “cornerstone in DiaGenic’s communication towards [the] market in Europe.”
DiaGenic has developed array and RT-PCR-based assays for Alzheimer’s disease and breast cancer. The company partnered with UK-based Opaldia last December to offer a research-only version of its early stage breast-cancer test to private clinics. Opaldia has also secured the rights to sell DiaGenic’s early-stage Alzheimer’s test in the UK when it becomes available (see BAN 12/18/2007).
Meantime, the company is working with an undisclosed Indian lab to eventually bring the breast cancer test to the Indian market by the end of this year. Christensen said that DiaGenic’s global strategy is to enter into partnerships, such as the one with Opaldia, to make its tests available rather that entering the market on its own.
The company believes that having its patents protected in as many countries as possible will help it secure more partnerships and facilitate the launch of its diagnostics as they become available.
“We are creating good protection within this diagnostic field,” he said. “We have a goal of ********* protection for our technology and patent applications are in process in all major markets,” said Christensen. “There are different speeds for different countries. So we will still have ongoing applications in Europe and US about other diseases in this area.”
Europe, India, US
As evidenced by the deal with Opaldia, DiaGenic plans to debut its first diagnostics in Europe, taking advantage of the relatively simple process for obtaining a CE Mark. “In Europe it is a speedier approach” than in the US, he said. “We plan to have EU approval of both our breast cancer and Alzheimer’s tests by the end of this year, and we are looking forward to having revenues in the second half of this year from our partnership in the UK that will increase into 2009.”
The company will also try to enter the Indian market with help from its undisclosed partner. Christensen said that patent coverage in India sends an “important signal” that DiaGenic is protected.
“We are looking into strategic partnerships in India to have long-lasting cooperation for targeting that market,” he said. “For the major players in that marketplace IP is important.”
DiaGenic originally developed its tests to run on Applied Biosystems’ RT-PCR TaqMan 7900 HT platform as well as on Applied Microarrays’ CodeLink bioarray platform. Christensen said that, for now, both Opaldia as well as DiaGenic’s India partner will be using the 7900 to run the breast cancer assays.
“One of the reasons for success in India is the use of these cartridges,” Christensen said of the 7900 platform. “Because it is a more closed system with microflidics inside, it can sustain the environment and challenges of India,” he said. “Due to a strike, our cartridges were stuck for weeks in customs in India in 40° [Celsius, 104° Fahrenheit] temperatures, and they were not destroyed.”
Christensen said that DiaGenic has had an extensive relationship with Applied Biosystems and that the firm might count on ABI as a partner when it eventually seeks to bring its tests to the US market. He said that ABI’s planned spinout from *****ra this summer could kickstart talks about deeper collaboration.
“Then it will be ABI’s liberty to make decisions within their field that won’t be restricted by *****ra’s diagnostic preference,” he said. “From my point of view it is an interesting development within ABI, and we have had a long relationship with them.”

DISTRIBUTION OF DIAGNOSTIC TEST IN INDIA:
April 29 2008

DiaGenic signs Memorandum of Understanding for distribution of breast
cancer test.
During the last months DiaGenic has negotiated distribution arrangements
for the breast cancer test in India, which will be the first commercial
launch of a DiaGenic diagnostic product. There are currently two
partners on the shortlist, and today the board of directors of DiaGenic
has approved a signed Memorandum of Understanding (MoU) between DiaGenic
and SRL Ranbaxy Ltd., concerning SRL Ranbaxy becoming partner in the
India and ancillary territory for DiaGenic's diagnostic test for breast
cancer. A final agreement shall imply that SRL Ranbaxy, the largest
laboratory chain in India with more than 700 hundred collection centres
and laboratories over the entire region, will market and sell the test.
SRL Ranbaxy will also be responsible for the collection of blood
samples. The samples will be analysed at LabIndia Instruments Pvt. Ltd.
DiaGenic will receive a Technical Services Fee of INR 2.500 per test
sold. The Indian clinical trials and commercial setup has been
coordinated by DiaGenic's Indian partner, PAC Med Biotech Pvt. Ltd.
After deduction of costs to PAC Med Biotech, DiaGenic will receive
approximately NOK 300 per test at present foreign exchange rates. The
price level of the test and the corresponding payment to DiaGenic is
expected to vary between markets, with the Indian price expected to be
at the lower end.
Praveen Sharma, co-founder and Technology and Product Development
Director of DiaGenic comments:
"The agreement marks DiaGenic's entry into a new phase where marketing
and sales will stand central in the realization of company's goal of
becoming a premier global molecular diagnostic company. It is to my
great satisfaction that this agreement will make it possible to first
launch our test in India, which happens to be my home country. The two
companies on the shortlist will both be able to make the test widely
available in the huge Indian market. There is an increasing need for
DiaGenic's test in India. The incidence of breast cancer is rising among
younger women, and nationwide screening program is lacking. There is low
rate of survival due to late discovery and women are becoming more aware
of the disease."

Read this:


http://lifestyle.in.msn.com/health/a...mentid=1362458

Breast cancer will become epidemic in India'
Breast cancer is the most common form of cancer among women. According to a study by International Agency for Research on Cancer, there will be approximately 250,000 new cases of breast cancer in India by 2015. At present, India reports around 100,000 new cases annually

PRIVATE PLACEMENT COMPLETED

Reference is made to the announcement issued by DiaGenic ASA on 7 May 2008 regarding the contemplated private placement of shares. The private placement of 8 million shares is completed at a subscription price of NOK 5,60 per share.The Board of Directors of DiaGenic has on 7 May 2008 approved a private placement of 8 million new shares (corresponding to approximately 18,3 % of existing shares of the company ) at a subscription price of NOK 5,60 per share. The total gross proceeds from the private placement equal NOK 44,8 million. The shares were placed among Norwegian and international investors.The transaction was executed by Kaupthing.Following registration of the new shares issued in the private placement, the number of shares in DiaGenic will increase from 43 736 520 to 51 736 520 each with a par value of NOK 0.05, and the share capital will increase from NOK 2 186 826 to NOK 2 586 826.Oslo, May 7, 2008

23/05-2008 14:43:57: (DIAG) DISTRIBUTION AGREEMENT FOR INDIA

Breakthrough - I recommend to buy this share now!
The upside potential is huge for Diagenic on the long turn!:smilie3:

DISTRIBUTION AGREEMENT FOR INDIA:)
Reference is made to the announcement issued by DiaGenic ASA on 29 April
2008 regarding signed "Memorandum of Understanding" (MoU) with SRL
Ranbaxy LTD for distribution of Diagenic's breast cancer test in India.
The negotiations are now concluded and the distribution agreement is
signed by both parties.
DiaGenic has been negotiating with key partner candidates for the
distribution of the breast cancer test in India. Following the signed
MoU's the negotiations have been continued with both of the two
candidates on the short list. Today, the board of directors of DiaGenic
has confirmed its preference for the largest laboratory chain in India;
SRL Ranbaxy LTD, and the parties have signed the distribution agreement.
The agreement implies that SRL Ranbaxy will become the commercial
partner for DiaGenic's diagnostic test for breast cancer in India and
ancillary territory. SRL Ranbaxy, the largest laboratory chain in India
with more than 700 hundred collection centres and laboratories over the
entire region, will market and sell the test. SRL Ranbaxy will also be
responsible for the collection of blood samples.
DiaGenic will receive a Technical Services Fee of INR 2.500 per test
sold. After deduction of the agreed costs to DiaGenic's Indian agent,
DiaGenic will receive approximately NOK 300 per test (at present foreign
exchange rates). Further, the agreement implies an obligation for SRL
Ranbaxy to invest substantially in marketing of the test during the
first year. The agreement is mutually exclusive, and contains clauses
about minimum volumes as from year two. Numbers for minimum volumes and
the investments in marketing are not disclosed.
The parties have worked out a joint international press release about
the agreement; please find this press release enclosed.
Newsweb

Today, it is a matter of pride only that even High-end Hospitals from UK and Middle East are sending their test requirements to SRL Ranbaxy.

Sanjeev K. Chaudhry, CEO of SRL Ranbaxy predicts high demand for the DiaGenic test, “Awareness of breast cancer is growing in India and with SRL Ranbaxy reaching out to serve the maximum number of Gynecologists and Oncologists in the country, it would enable them to actively promote the cause of women’s health in India, with increased care and concern. We believe the DiaGenic test will provide the perfect incentive for women to take charge of their health and undergo regular check-ups. SRL Ranbaxy will put in place intensive and extensive market facing strategies to ensure rapid growth in the market, both locally and internationally, and will invest substantial amounts and efforts to inform the market on the availability of this new innovative test. “

Breakthrough - I recommend to buy this share now!
The upside potential is huge for Diagenic on the long turn!

Sanjeev K. Chaudhry, CEO of SRL Ranbaxy

predicts high demand for the DiaGenic test, "Awareness of breast cancer is growing in India and with SRL Ranbaxy reaching out to serve the maximum number of Gynecologists and Oncologists in the country, it would enable them to actively promote the cause of women’s health in India, with increased care and concern. We believe the DiaGenic test will provide the perfect incentive for women to take charge of their health and undergo regular check-ups. SRL Ranbaxy will put in place intensive and extensive market facing strategies to ensure rapid growth in the market, both locally and internationally, and will invest substantial amounts and efforts to inform the market on the availability of this new innovative test.